Browser storage is unavailable. Keep this page open and export your collection before leaving.
Biotech pharma

Synkrino Biotherapeutics
Overview
Synkrino's AI, SATIS is a powerful, unbiased discovery system for…
Company description As recorded 2026-11-08
Founders & team
Previously SF17 Therapeutics
Company history As recorded 2026-11-08
Founder profile As recorded 2026-09-15
David Ott
Founder/CTOFounder profile As recorded 2026-09-15
2team members reported
Source-reported As recorded 2026-09-15
News & product activity
Cohort membership
Summer 2018Summer 2018
Original evidence ↗Sources & observations
Profile depthverified profile
Website observationwebsite unreachable
Last website check2026-11-11
Location · source statedSan Francisco, CA, USA; Oakland, CA, USA
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 3 of 6 areas documented
Source-based assessment · automated evidence rules
The latest website check does not confirm this company’s website.
Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.
- Product overviewSource description Checked 2026-11-08
- Product visualsNot documented
- Founders & originsTeam information
- Business model & pricingNot documented
- Funding & ownershipNot documented
- Dated milestonesDated source activity: 2018 Q3 (quarter only)
independent websitesource corroborationdescriptive evidenceclassified market and modelsourced people





